Condition

Measles

Clinical trials and treatment information for Measles

132K

People Affected

Active Trials

New Cases/Year

56K

Deaths/Year

Treatment Rankings

Ranked by evidence volume first. Medicine has spent centuries ranking things by vibes. This is an improvement.

Measles, Mumps, and Rubella (MMR) Vaccine

97% Effectiveness• 98% Confidence• 75% Safety• 69 trials• 10M participants

HIGH EvidenceExcellent ValueDose: 0.5 mL subcutaneous injection

Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️

Meth💀

Cigarettes🚬

Chemo☢️

Alcohol🍺

Morphine💊

Antibiotics💉

Tylenol💊

Exercise🏃

Water💧

DangerousModerateSafe

Time to Effect

2-4 weeks for immunity

Duration

Two doses in childhood for long-term immunity

Response Rate

Remission Rate

Number Needed to Harm (NNH)

1000000

Common Side Effects:

Fever: 15%

Mild rash: 5%

Temporary joint pain (adult women): 25%

Swelling of glands in cheeks or neck: 1%

Serious allergic reaction: 0.0001%

Annual Cost of Care

Drug Cost

$70

Monitoring

Side Effects

Total Annual

$76

Cost-Effectiveness

EXCELLENT

QALYs Gained

0.5

ICER

$1,000/QALY

Treatment Outcomes

Primary Outcomes

Risk of Measles Infection90% probability of infection upon exposure (unvaccinated, susceptible)

-97% (-87.3 percentage points (reduction in infection probability))

Risk of Mumps Infection80% probability of infection upon exposure (unvaccinated, susceptible)

-88% (-70.4 percentage points (reduction in infection probability))

Risk of Rubella Infection70% probability of infection upon exposure (unvaccinated, susceptible)

-97% (-67.9 percentage points (reduction in infection probability))

Measles-Related Hospitalization Rate25 hospitalizations per 1,000 Measles cases (among unvaccinated)

-99% (-24.75 hospitalizations per 1,000 Measles cases)

Measles-Related Mortality Rate1.0 death per 1,000 Measles cases (among unvaccinated in developed countries)

-99.9% (-0.999 deaths per 1,000 Measles cases)

Secondary Benefits

Incidence of Congenital Rubella Syndrome (CRS)1 case per 4,000 live births (pre-vaccine era annual incidence)

-99.9% (-0.999 cases per 4,000 live births)

Incidence of Mumps-Related Complications1.0 complication per 1,000 population per year (in unvaccinated populations)

-95% (-0.95 complications per 1,000 population per year)

Annual Healthcare Costs for MMR Diseases$500,000,000 per year (estimated pre-vaccine era total costs in a large developed country)

-99% (-$495,000,000 per year)

Common Side Effects

Fever

+15%

Mild rash

+5%

Temporary joint pain (adult women)

+25%

Clinical Trial Phases:

Phase 4

Vitamin A Supplementation

80% Effectiveness• 90% Confidence• 85% Safety• 1 trials• 30K participants

HIGH EvidenceExcellent ValueDose: Oral; 50,000 IU (<6 mos), 100,000 IU (6-11 mos), 200,000 IU (>=1 year)

Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️

Meth💀

Cigarettes🚬

Chemo☢️

Alcohol🍺

Morphine💊

Antibiotics💉

Tylenol💊

Exercise🏃

Water💧

DangerousModerateSafe

Time to Effect

Within days

Duration

2 days (two doses)

Response Rate

85%

Remission Rate

Number Needed to Treat (NNT)

180

Number Needed to Harm (NNH)

100

Common Side Effects:

Temporary headache: 10%

Nausea: 5%

Vomiting: 5%

Bulging fontanelle (infants): 1%

Annual Cost of Care

Drug Cost

$0.1

Monitoring

$600

Side Effects

Total Annual

$600.1

Cost-Effectiveness

EXCELLENT

QALYs Gained

0.15

ICER

$500/QALY

Cost per Responder

$0.12

Treatment Outcomes

Primary Outcomes

Measles-related Mortality3.5% (mortality rate in untreated measles patients)

-50% (-1.75 percentage points)

Incidence of Pneumonia30% (of measles patients developing pneumonia)

-30% (-9 percentage points)

Incidence of Severe Diarrhea45% (of measles patients experiencing severe diarrhea)

-25% (-11.25 percentage points)

Incidence of Ocular Complications (Corneal Ulceration)2% (of measles patients developing corneal ulceration)

-70% (-1.4 percentage points)

Secondary Benefits

Duration of Fever4.0 days (average duration)

-15% (-0.6 days)

Duration of Hospital Stay7.0 days (average duration)

-20% (-1.4 days)

Common Side Effects

Temporary headache

+10%

Nausea

+5%

Vomiting

+5%

Clinical Trial Phases:

Phase 4

Supportive Care (Fluid Management, Antipyretics, Nutritional Support)

90% Effectiveness• 95% Confidence• 85% Safety00

HIGH EvidenceExcellent ValueDose: Individualized based on patient needs and symptoms

Find Trials

Comparative Safety Scale(Higher is safer)

Cyanide☠️

Meth💀

Cigarettes🚬

Chemo☢️

Alcohol🍺

Morphine💊

Antibiotics💉

Tylenol💊

Exercise🏃

Water💧

DangerousModerateSafe

Time to Effect

Immediate symptom relief/stabilization

Duration

7-14 days (duration of acute illness)

Response Rate

95%

Remission Rate

95%

Common Side Effects:

Over-hydration: 0.1%

Electrolyte imbalance: 0.1%

Gastrointestinal upset (antipyretics): 5%

Liver toxicity (antipyretic overdose): 0.01%

Annual Cost of Care

Drug Cost

$15

Monitoring

$200

Side Effects

$10

Total Annual

$225

Cost-Effectiveness

EXCELLENT

Cost per Remission

$236.84

Cost per Responder

$236.84

Treatment Outcomes

Efficacy Outcomes

Overall Effectiveness

+90%

Response Rate

+95%

Remission Rate

+95%

Common Side Effects

Over-hydration

+0.1%

Electrolyte imbalance

+0.1%

Gastrointestinal upset (antipyretics)

+5%